US Stock Futures Steady as Nvidia Rebound Lifts Wall Street by Mark Eisenberg 26.06.2024 US stock futures steady as Nvidia rebound boosts Wall Street; caution lingers ahead of key inflation data likely to impact ...
Howard Hughes Holdings: Exec Buys Stock Amid Housing Boom by Mark Eisenberg 26.06.2024 "Howard Hughes Holdings Exec Elena Verbinskaya shows confidence in company by purchasing $22,390 in stock amid key developments and financial ...
22nd Century Group Cuts $1.5M Debt, Extends Loan Balance by Mark Eisenberg 26.06.2024 22nd Century Group cuts debt by $1.5M, aiming for financial stability and progress in tobacco harm reduction using advanced technology.
FedEx Stock Soars as Profit Beats Analyst Forecasts by Mark Eisenberg 26.06.2024 "FedEx stock soars 15% as Q4 earnings and revenue beat forecasts; DRIVE program aids cost-cutting; EPS for 2025 also surpasses ...
Microsoft’s Gen-AI Outpaces Azure in CapEx Efficiency, Says Goldman by Mark Eisenberg 25.06.2024 "Microsoft's Gen-AI investments yield high capital efficiency, with AI revenue growth surpassing early Azure benchmarks, per Goldman Sachs."
Kenya Erupts in Protests After Controversial Finance Bill by Mark Eisenberg 25.06.2024 Kenya’s controversial finance bill ignites violent protests, resulting in 10 deaths, Parliament arson, and widespread national unrest.
Nissan to Produce Dongfeng’s Voyah EVs by Year-End by Mark Eisenberg 25.06.2024 Nissan to start producing EVs for Dongfeng by year-end to reduce costs and boost factory utilization, amid rising competition in ...
HireQuest CEO Buys $12.9K in Stock Amid Market Struggles by Mark Eisenberg 25.06.2024 HireQuest CEO buys $12.9K in shares, signaling strong confidence in company’s future amidst tough market and positive Q1 financials.
iClick Interactive Faces Nasdaq Compliance Hurdle Amid Adjustments by Mark Eisenberg 25.06.2024 "iClick Interactive reviews operations after Nasdaq compliance warning for delayed 2023 filing; appoints new CFO amid market and revenue challenges."
ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...